Coronavirus | 72 therapeutics trial underway, 211 in planning stages: FDA

To date, the FDA has issued 44 individual emergency use authorisations for test kit manufacturers and laboratories

April 25, 2020 07:22 am | Updated 07:27 am IST - Washington

Image used for representation purpose only.

Image used for representation purpose only.

A top Trump administration health official has said that as many as 72 COVID-19 therapeutics trial are underway and 211 in planning stages in a bid to find the cure for coronavirus.

“We are leaving no stone unturned to find the treatment for COVID-19... We don’t have any approved therapeutics for COVID-19 but we are actively involved with the academic, commercial and private sector to find it,” FDA Commissioner Stephen M. Hahn told reporters at a White House news conference.

“Seventy-two trials of therapeutics are underway in the United States under FDA oversight and 211 are in the planning stages, so we expect to see more. This includes convalescent plasma as well as antiviral therapies,” Hahn added. According to Hahn, work is continuing on finding a vaccine. FDA has authorised two firms on vaccine trials.

Hahn said that the FDA has told manufacturers that in order to market anti-body tests in the U.S., they have to validate their tests. So far, the U.S. has authorised four and more are in the pipeline, he added.

The FDA is also helping make antibody tests that are used to detect natural immunity these “These are just one part of FDA’s larger response effort. They can play a role in helping move the economy forward by helping healthcare professionals identify those who have immunity to the COVID-19,” he asserted.

During the COVID-19 pandemic, the FDA has worked with more than 380 test developers who have said they will be submitting emergency use authorisations (EUA) requests to FDA for tests that detect the virus. To date, the FDA has issued 44 individual emergency use authorisations for test kit manufacturers and laboratories. In addition, 19 authorised tests have been added to the EUA letter of authorisation for high complexity molecular-based laboratory developed tests (LDTs).

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.